Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient

Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form of uveitis, in her left eye 2 weeks after starting dupilumab treatment, which improved after reducing the dose, without discontinuing dupilumab. The patient also experienced asymptomatic hypereosinophilia, possibly related to dupilumab, which was gradually relieved without discontinuation. With the readers, we share our experience in managing uveitis and hypereosinophilia associated with dupilumab, which may be helpful in managing these conditions and avoiding discontinuation of dupilumab.

Automated summary

In this article, a case of a 28-year-old female with atopic dermatitis who developed uveitis and hypereosinophilia after starting dupilumab treatment is reported. The uveitis improved with reduced dose and the hypereosinophilia gradually relieved without discontinuation of dupilumab. The authors share their experience in managing these conditions and suggest that discontinuation of dupilumab may not always be necessary.